AlphaCentric Advisors’s BioXcel Therapeutics BTAI Stock Holding History

AlphaCentric Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,500	Closed	-$746K	–	237
2023 Q1	$746K	Sell	2,500 -625	-20%	-$267K	0.52%	68
2022 Q4	$1.07M	Hold	3,125	–	–	1.06%	30
2022 Q3	$591K	Buy	+3,125	New	+$726K	0.61%	52
2021 Q4	$1.02M	Buy	3,125 +937	+43%	+$402K	0.3%	31
2021 Q3	$1.06M	Buy	2,188 +625	+40%	+$275K	0.27%	24
2021 Q2	$727K	Hold	1,563	–	–	0.2%	40
2021 Q1	$1.08M	Hold	1,563	–	–	0.36%	22
2020 Q4	$1.16M	Buy	1,563 +313	+25%	+$244K	0.48%	14
2020 Q3	$867K	Sell	1,250 -313	-20%	-$235K	0.42%	16
2020 Q2	$1.32M	Buy	+1,563	New	+$1.02M	0.75%	6

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AlphaCentric Advisors's BTAI Position: Q2 2023 in Review

AlphaCentric Advisors sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 2,500 shares — an estimated $746K sold.

AlphaCentric Advisors first reported a position in BTAI in Q2 2020 and held it in 10 quarters. The position peaked at $1.32M in Q2 2020. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

AlphaCentric Advisors reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
AlphaCentric Advisors sold 2,500 BioXcel Therapeutics shares in Q2 2023, an estimated $746K.
AlphaCentric Advisors first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 10 quarters.
AlphaCentric Advisors's BioXcel Therapeutics position peaked at $1.32M in Q2 2020.
88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.